Dry Eye

The industry-sponsored survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.

Acoltremon ophthalmic solution 0.003% usage was associated with improved performance in visual acuity tasks.

Catch up on the top stories in optometry during the week of August 24-28.

The company announced phase 2 results of a dual-action lifitegrast/perfluorohexyloctane dry eye drop alongside positive phase 1b results for BL1332, a first-in-class TRPV1 antagonist for ocular surface pain.

The FDA has expanded the indication to include improvement of meibomian gland function in adult patients with evaporative dry eye disease due to MGD, making it the first treatment with this indication.

Perceived stress modestly predicted later dry eye symptoms in young adults, but significance depended on a prespecified 1-tailed test.

Recommending omega-3 fatty acids in the diet of a patient with DED could lead to improved tear osmolarity and tear breakup time and thus fewer dry eye symptoms.

Harrow will acquire Tyrvaya, the only FDA-approved nasal spray for dry eye disease, from Viatris for around $100 million, complementing its cyclosporine product Vevye.

A disconnect between the signs and symptoms of OSD can easily lead to misdiagnosis or undertreatment if clinicians rely solely on a slit lamp observation.

Esen K. Akpek, MD, speaks with the Eye Care Network in recognition of Dry Eye Awareness Month.

The approval is backed by Phase 3 bridging data—expanding EyeSol options and intensifying market rollout.

According to the survey, one in five sufferers reported that dry eye symptoms affect their self-confidence (22%) and emotional wellbeing (20%).

A retrospective study of 27 dry eye patients found adjunctive preservative-free periocular skincare significantly reduced periocular erythema and MGD severity over 28 days, with 93% of patients reporting intent to continue use.

New preservative-free cyclosporine 0.05% single-use drops target dry eye inflammation, dosing, and safety.

Oculis launches a genotype-guided dry eye trial testing licaminlimab eye drops, targeting TNFR1 patients and measuring Day 29 ocular discomfort improvement.

The product is expected to be available in stores and online at Amazon, CVS, Target and Walgreens by the end of June 2026.

Upsher-Smith launched generic cyclosporine ophthalmic emulsion 0.05% in the US for tear production in inflammatory dry eye.

Mitch Ibach, OD, FAAO; Nate Lighthizer, OD, FAAO; and Austin Lifferth, OD, FAAO, share practical insights on identifying early disease and more.

NUS researchers report that plant-based photosynthetic nanoparticles restored corneal NADPH levels and reversed damage within 5 days in preclinical dry eye.

Jessilin Quint, OD, MBA, MS, FAAO, shares strategies for improving adherence, building trust through patient communication, and more.

Knowing the shared signs and symptoms can lead to proper diagnosis.

The videos provide an overview of the report, review the diagnostic methodology section, and highlight key points from the management and therapy report.

The launch is supported by results from a phase 3 randomized, double-masked, placebo-controlled trial (3-02).

Several presentations at ASCRS 2026 spotlight faster dry eye relief and smarter pre-operative care, showing lifitegrast and new drugs can ease symptoms quickly and improve cataract biometry.

The study demonstrates that Corynebacterium mastitidis, a bacterium that resides on the ocular surface, can be genetically modified to secrete the anti-inflammatory cytokine interleukin-10.